Clinical trial NCT01142089: Study to Evaluate Safety and Efficacy of Rifamycin SV Multi-Matrix System (MMX) for the Treatment of Traveler's Diarrhea (TD)
Official title: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Rifamycin SV MMX for the Treatment of Traveler's Diarrhea
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Traveler's Diarrhea
Keywords: traveler's
diarrhea
Rifamycin SV MMX
Rifamycin
MMX
Traveler's Diarrhea
Lead sponsor: CosmoTech
Sponsor class: UNKNOWN
Collaborators: name: Bausch Health Americas, Inc.
First posted: 2010-06-11
Enrollment: 264
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine whether Rifamycin SV MMX is a safe and effective treatment for Traveler's Diarrhea.

Detailed description: This is a multicenter, randomized, double-blind, placebo-controlled efficacy and safety study conducted in patients traveling to developing regions with a known high incidence of TD. Eligibility will be based on a symptom complex that is highly indicative of enteric acute bacterial infection without indication of systemic infection.

Approximately 262 patients will be enrolled in the study and randomized at a 3:1 ratio to receive Rifamycin SV MMX® 400 mg or placebo orally twice daily for 3 days (72 hours). Treatment will be initiated on the day of Screening (Visit 1, Day 1), within 72 hours of onset of diarrhea. Daily doses of study drug will be taken at breakfast time and dinner time with a glass of liquid.

Safety and efficacy will be assessed.

Blood samples for routine safety tests (chemistry and hematology) will be collected at Visit 1 and at Visit 3 and sent to a local laboratory for analysis and reporting to the Investigator for safety monitoring. Urine samples for routine urinalysis (dipstick only) will be collected at Visits 1 and 3, and the results will be used by the Investigator for safety monitoring.

If a patient's diarrhea and/or signs or symptoms of enteric infection worsen in a 24 hour interval of time during the treatment period or if the enteric illness fails to improve after 24 hours or more of therapy, the patient may receive Rescue Therapy. Rescue Therapy will be prescribed by the Investigator using local standard empiric therapy and/or guided by pathogen identification.

Eligibility criteria: Inclusion Criteria

Patients were enrolled in the study only if they met all of the following criteria:

1. Male and female patients 18 years of age or older
2. Female and male patients of childbearing potential must have agreed to use an effective method of birth control (this method must have been approved by the investigator and may have included total abstinence from sexual intercourse) during the treatment and follow-up study periods; female patients of childbearing potential must have had a negative pregnancy test in the 72 hours before randomization; female patients who abstained totally from sexual intercourse were not required to take the pregnancy test
3. Recent travel (i.e., must be within 30 days of randomization) from an industrialized country
4. Experiencing signs or symptoms indicative of acute bacterial diarrhea (TD), defined as at least three unformed, watery or soft, stools within the 24 hours preceding randomization and the duration of illness 72 hours before randomization, and able to provide an unformed stool sample during Screening (the latter can be the third unformed stool passed by the patient within the 24 hours preceding randomization); the bacterial cause of diarrhea was confirmed by microbiology analysis of the stool sample
5. Experiencing one or more signs or symptoms of enteric infection (moderate to severe gas/flatulence, nausea, vomiting, abdominal cramps or pain, rectal tenesmus, or defecation urgency)
6. Capable of and willing to give informed consent

Exclusion Criteria

Patients were excluded from the study if they met any of the following criteria:

1. Fever (\> 100.4F or 38C) or presence of signs and symptoms of systemic infection Note: antipyretic medication should not have been administered in the 6 hours before this assessment
2. Known or suspected infection with non-bacterial pathogen before randomization
3. Presence of diarrhea for \> 72 hours duration
4. Presence of grossly bloody stool
5. Presence of moderate to severe dehydration (i.e., presence of orthostatic hypotension and/or dehydration requiring treatment with intravenous fluids)
6. History of ulcerative colitis, diarrhea-predominant irritable bowel syndrome, Crohn's disease, celiac sprue (gluten-enteropathy), chronic pancreatitis, malabsorption, or any other gastrointestinal disease associated with diarrhea. Note: lactose intolerance treated with lactase supplements or a lactose-free diet were not excluded if these regimens were maintained during the study.
7. Receiving more than two doses of an antidiarrheal medication (e.g., antimotility, absorbent, adsorbent, antisecretory, or probiotics) within 24 hours before randomization
8. Receiving one or more of the following antibiotics, which are active against gram negative bacteria TMP-SMX, fluorquinolone, azithromycin or rifaximin within 7 days before randomization
9. Females pregnant or breast feeding or not using adequate birth control
10. Known intolerance/hypersensitivity/resistance to rifamycin or rifamycin-related antibiotics or to any excipient included in the study medications
11. Patients unable or unwilling to comply with study protocol (e.g., alcoholism, mental illness, travel schedule)
12. Participation in a clinical study with another investigational drug in the 30 days prior to randomization or while participating in this study
13. Previous participation in this study

Primary outcomes:
measure: Time to Last Unformed Stool (TLUS)
timeFrame: 24 hours
Secondary outcomes:
measure: Clinical Cure
timeFrame: 24 hours
Other outcomes:
Locations:
city: Antigua
country: Guatemala
facility: Santarus Investigational Site 03
city: Antigua
country: Guatemala
facility: Santarus Investigational Site 14
city: Quetzaltenango
country: Guatemala
facility: Santarus Investigational Site 04
city: Guadalajara
country: Mexico
facility: Santarus Investigational Site 05
state: Jalisco
city: Cuernavaca
country: Mexico
facility: Santarus Investigational Site 06
state: Morelos
city: Cabo San Lucas
country: Mexico
facility: Santarus Investigational Site 12
city: Cancun
country: Mexico
facility: Santarus Investigational Site 10
city: Oaxaca
country: Mexico
facility: Santarus Investigational Site 07
city: Puebla
country: Mexico
facility: Santarus Investigational Site 08
city: Puerto Escondido
country: Mexico
facility: Santarus Investigational Site 09
city: Puerto Vallarta
country: Mexico
facility: Santarus Investigational Site 11
city: Tulum
country: Mexico
facility: Santarus Investigational Site 13
Study officials:
affiliation: Bausch Health Americas, Inc.
name: Herbert DuPont, MD
role: PRINCIPAL_INVESTIGATOR
References: